

INVION GENERAL MEETING: CEO UPDATE

Melbourne, Australia, 30 January 2019: Invion Limited (ASX:IVX) is pleased to provide the CEO's Update to be presented to the Company's General Meeting being held today at 12.00pm at The Clarendon, 209-215 Clarendon Street, South Melbourne, Victoria.

About Invion

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: investor@inviongroup.com

INVION


EGM

Presentation

30 January 2019



2019 CONTINUED PROGRESS POST AGM



JAN 2019:

Invion strengthens Scientific Advisory Board - appoints three cancer experts

Invion announced to the market the strengthening of its Scientific Advisory Board, through the appointment of three experts in skin, lung and prostate cancer – recognised areas of future development of the company.

New appointees are:

- Dr Lynda Spelman (skin cancer) - a specialist dermatologist with 26 years' experience in dermatology and a special interest in clinical research trials. She is the founder and a director of the Queensland Institute of Dermatology and a principal investigator for Veracity Clinical Research.
- Assoc. Prof Louis Irving (lung cancer) - A Specialist lung cancer and respiratory physician at the Peter MacCallum Cancer Centre, and director of clinical training at Royal Melbourne Hospital. He also holds principal fellowships at the University of Melbourne, in the Faculty of Medicine and the Department of Physiology.
- Assoc. Prof Nathan Lawrentschuk (prostate cancer) - a urologic oncologist and director of the Urology Research Centre at Epworth Healthcare. He is also a urological surgeon and oncologist at the Peter MacCallum Cancer Centre, and holds appointments at the University of Melbourne's Department of Surgery and the Olivia Newton-John Institute for Cancer Research at the Austin Hospital, Melbourne.

JAN 2019:

Invion selects Guilin Xingda to manufacture light-therapy medical equipment


- Invion Ltd and Chinese specialist medical equipment maker Guilin Xingda Photoelectric Medical Device Co. Ltd Guilin Xingda Photoelectric Medical Device Co. Ltd sign manufacturing deal for medical equipment for use in photodynamic cancer therapies
- The collaboration is focussed on the development of medical light sources to suit skin, ovarian, prostate and lung cancer
- Invion will now be able to offer a “total solution’ for PDT treatment options the the supply of the medical light equipment and IVX-PO2 (currently being developed for the treatment of a range of cancers)

1H 2019:

Commercial and development targets

- Completion of spin-out of respiratory assets
- Gel formulation of improved photosensitiser product IVX-P02 for the treatment of skin cancer targeted for testing in human clinical studies.
- Operational expansion into intravenous treatment uses for PDT treatment in lung and prostate cancer.

KEY MILESTONES AHEAD



Multiple programs due to enter human clinical trials in 2019

- **Topical Indications:**
 - Skin cancer BCC
 - Actinic Keratosis
- **Intravenous Indications:**
 - Ovarian
 - Lung
 - Prostrate

MARKET OVERVIEW


\$0.018

(At 28 January 2019)

**Mkt. Cap.
A\$98.86m**

(At 28 January 2019)

Focus	Clinical-stage life sciences company
Issued Shares	5,492,272,967
Cash (At 30 Sep 2018)	AUD \$1.647M
Funding	Invion has an R&D services agreement with The Cho Group who provide non-dilutive funding for the clinical development of Photosoft™ technology.
Symbol	IVX
Exchange	ASX



Substantial shareholders	%IC
UNLIMITED INNOVATION GROUP LIMITED	51.24
POLAR VENTURES LIMITED	9.93
MR HONSUE CHO	5.17

INVION[™]